Happify Health has raised $73m in series D funding to advance and expand its digital healthcare platform with focus on digital therapeutics and patient care delivery.

Deerfield Management Company led the investments that also include participation from Omega Capital Partners, ION Crossover Partners, and other existing investors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Happify Health, which is a global software-enabled healthcare platform, will use the funding to expand the Digital Therapeutics and Care Delivery solutions and pursue global business development opportunities.

The capital funding will further help to drive relationships with pharmaceutical companies through configurable digital therapeutics solutions and specialised solutions for enterprise and health plan customers.

Happify Health co-founder and CEO Tomer Ben-Kiki said: “Our ability to add a well-rounded group of seasoned investors, led by Deerfield, will further prepare us to execute against the tremendous opportunity ahead of us.

“Today, our platform covers more than 20 million lives with more than 5 million individuals having received care through our platform.

“We are also working with five leading pharmaceutical partners on digital therapeutic solutions and four out of the five national payors to help support their members’ mental health and chronic illness needs. We look forward to reaching an even bigger audience with the support of our new partners.”

The funding will also support additional investment in developing advances in Artificial Intelligence and Machine Learning-based models that power Anna.

Anna is a software-based coach which is designed to support and engage individuals for various chronic conditions, most particularly mental health.